PURPOSE: To compare the efficacy and safety of latanoprost, bimatoprost, travoprost and @entity6839 in @entity2790 (IOP) in @entity1 with primary @entity1538 . METHODS: This was a prospective study conducted at a tertiary-care centre. One hundred and forty @entity1 with newly diagnosed primary @entity1538 were randomly assigned to treatment with latanoprost (0.005%), bimatoprost (0.03%), travoprost (0.004%) or @entity6839 gel (0.5%); 35 @entity1 were assigned to each group. All @entity1 were followed for 2, 6, and 12 weeks. The main outcome measure studied was the change in IOP at week 12 from the baseline values. Safety measures included recording of adverse events. RESULTS: The mean IOP reduction from baseline at week 12 was significantly more with bimatoprost (8.8 mmHg, 35.9%) than with latanoprost (7.3 mmHg, 29.9%), travoprost (7.6 mmHg, 30.8%) or @entity6839 (6.7 mmHg, 26.6%) (ANOVA and Student's t-tests, p < 0.001). Among the prostaglandins studied, bimatoprost produced a maximum reduction in IOP (-2.71; 95% confidence interval [CI], -2.25 to -3.18) followed by travoprost (-1.27; 95% CI, -0.81 to -1.27) and latanoprost (-1.25; 95% CI, -0.79 to -1.71); these values were significant when compared to @entity6839 at week 12 (Bonferroni test, p < 0.001). Latanoprost and travoprost were comparable in their ability to reduce IOP at each @entity1 visit. Ocular adverse-events were found in almost equal proportion in @entity1 treated with bimatoprost (41.3%) and travoprost (41.9%), with a higher incidence of @entity3169 (24.1%) seen in the bimatoprost group. @entity6839 produced a significant drop in heart rate (p < 0.001) at week 12 when compared to the baseline measurements. CONCLUSIONS: Bimatoprost showed greater efficacy when compared to the other @entity2918 , and @entity6839 was the most efficacious at lowering the IOP. Conjunctional @entity450 was mainly seen with bimatoprost. However, the drug was tolerated well and found to be safe.

Comparing the efficacy of latanoprost (0.005%), bimatoprost (0.03%), travoprost (0.004%), and XXXX (0.5%) in the treatment of primary @entity1538 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1538 :: ('MESH:D005902', 'Disease') :: ['open angle glaucoma'] @entity6839 :: ('MESH:D013999', 'Chemical') :: ['timolol', 'Timolol'] @entity2918 :: ('MESH:D011453', 'Chemical') :: ['prostaglandins'] @entity450 :: ('MESH:D006940', 'Disease') :: ['hyperemia'] @entity2790 :: ('MESH:D009798', 'Disease') :: ['reducing intraocular pressure'] @entity3169 :: ('MESH:D003229', 'Disease') :: ['conjunctival hyperemia']
@entity6839 :: (MESH:D013999,Chemical) :: ['timolol']
